PSIP1

Across TCGA pan-cancer cohorts, PSIP1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSIP1 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PSIP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSIP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LIHC, and CHOL are the cancer types where PSIP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.311	0.699	<.001	39	view →
LIHC	DFS	Median	All	0.084	0.546	<.001	30	view →
CHOL	OS	Median	All	0.019	0.800	<.001	24	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.941	0.829	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSIP1–HNSC (DFS)

Open the HNSC breakdown →